Evidence map›Paper›PMID 40754564›Full record

ReviewMedical oncology (Northwood, London, England)2025

Detecting vascular normalization in epithelial ovarian cancer.

Jânio da S Mororó, Débora D Meira, Solange M D Bizzo, Lorena S C Altoé, Matheus C Casotti, Gabriel M Santana, Luana S Louro, Thomas E S Louro, Creuza R Vicente, Bruno C de Araújo and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jânio da S Mororó *Departamento de Química Fundamental, Instituto de Química, Universidade de São Paulo (USP), São Paulo, Brazil. jmororo@alumni.usp.br.
Débora D Meira *Department of Biological Sciences, Universidade Federal Do Espírito Santo (UFES), Av. Fernando Ferrari, N. 514, Prédio Ciências Biológicas, Bloco A, Sala 106, Cep: 29.075-910, Vitória, Espírito Santo, Brazil. debora.meira@ufes.br.
Solange M D BizzoHospital Do Câncer 2, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.
Lorena S C AltoéDepartment of Biological Sciences, Universidade Federal Do Espírito Santo (UFES), Av. Fernando Ferrari, N. 514, Prédio Ciências Biológicas, Bloco A, Sala 106, Cep: 29.075-910, Vitória, Espírito Santo, Brazil.
Matheus C CasottiDepartment of Biological Sciences, Universidade Federal Do Espírito Santo (UFES), Av. Fernando Ferrari, N. 514, Prédio Ciências Biológicas, Bloco A, Sala 106, Cep: 29.075-910, Vitória, Espírito Santo, Brazil.
Gabriel M SantanaCentro de Ciências da Saúde, Curso de Medicina, Universidade Federal Do Espírito Santo, Espírito Santo, Brazil.
Luana S LouroCentro de Ciências da Saúde, Curso de Medicina, Universidade Federal Do Espírito Santo, Espírito Santo, Brazil.
Thomas E S LouroEscola Superior de Ciências da Santa Casa de Misericórdia de Vitória (EMESCAM), Curso de Medicina, Espírito Santo, Brazil.
Creuza R VicenteDepartamento de Medicina Social, Universidade Federal Do Espírito Santo, Espírito Santo, Brazil.
Bruno C de AraújoDepartment of Biological Sciences, Universidade Federal Do Espírito Santo (UFES), Av. Fernando Ferrari, N. 514, Prédio Ciências Biológicas, Bloco A, Sala 106, Cep: 29.075-910, Vitória, Espírito Santo, Brazil.
Sonia GroismanInstituto de Biologia Roberto Alcântara Gomes (IBRAG), Universidade Do Estado Do Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.
Elizeu F de CarvalhoInstituto de Biologia Roberto Alcântara Gomes (IBRAG), Universidade Do Estado Do Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.
Iúri D LouroDepartment of Biological Sciences, Universidade Federal Do Espírito Santo (UFES), Av. Fernando Ferrari, N. 514, Prédio Ciências Biológicas, Bloco A, Sala 106, Cep: 29.075-910, Vitória, Espírito Santo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is highly angiogenic, making this tumor attractive, in the last 20 years, for analysis of clinical and biological functions of the VEGF family, relating altered expression with patient's clinical responses. Currently, analyzes and validations have yet to be made to relate vascular normalization with combinations of immune-, chemo- or radiotherapy. We review the main clinical analyses capable of identifying markers of vascular normalization including functional biomarkers (e.g., perfusion parameters by imaging techniques), molecular biomarkers (e.g., circulating protein levels and cfDNA), blood biomarkers, physiological markers and other approaches. Many markers cited here have not yet been analyzed in EOC but have shown promising results in tumors such as pancreatic and glioblastoma cancer, which share similarities with ovarian cancer. The methodologies presented have the advantage of not being invasive and immediately detecting vascular normalization, mainly using imaging techniques.

Indexed as

Biomarkers, TumorCarcinoma, Ovarian EpithelialNeovascularization, PathologicOvarian NeoplasmsFemaleHumansBiomarkers, TumorAntiangiogenic therapyMicroenvironmentOvarian cancerPredictive therapy biomarkersVascular normalization

Identifiers

PMID40754564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.